Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
|Videos|October 6, 2020
FDA Advancements in HER2+ Breast Cancer
Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.
Advertisement
Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.
Advertisement
Related to this article
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Daisy Molina, EdD, MSN, RNC-LRN, details how nursing students learn to deliver hard news with empathy, plain language, and team support.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
Nicole Doell, MSN, RN, of Sylvester explains how nurses can address breast cancer misinformation without judgment and share vetted resources.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Teaching Communication as a Clinical Skill for Breast Cancer Care
2
Outpatient Tarlatamab Feasible in Community Oncology, Real-World Data Show
3
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
4
Survey: 40% of Community Practices Offer or Plan Cellular Therapy
5